Vaidya Chandra Prakash Cancer Research Foundation, Dehradun, Uttarakhand, India.
J Altern Complement Med. 2010 Feb;16(2):205-11. doi: 10.1089/acm.2008.0573.
Anemia is a serious health problem in Indian school children. High prevalence of anemia has been reported in nonpregnant adolescent girls. An investigation was initiated to study the effect of two non-iron-containing Ayurvedic preparations-Sootshekhar Rasa plus Sitopaladi Churna-in improving nutritional anemia among adolescent students.
This was a single-blinded, randomized, controlled study.
The study setting was Dehradun district, North India.
The subjects comprised a total of 1646 boys and girls, aged 11-18 years, attending school in Dehradun district.
As per World Health Organization guidelines, a total of 1322 adolescent anemic students were randomly divided into 5 groups. Students of group I (control) received starch. Group II, III, and IV students received Sootshekhar Rasa (SR) plus Sitopaladi Churna (SC) in various combinations, namely, SR 125 mg + SC 500 mg daily, SR 250 mg + SC 400 mg daily, and SR 250 mg + SC 400 mg weekly, respectively. Group V student were given iron and folic acid tablet. All the students received treatment for 90 days and were followed up for the next 180 days.
The outcome measure was to evaluate the effect of Sootshekhar Rasa plus Sitopaladi Churna in improving nutritional anemia.
The overall prevalence of anemia was found to be 81.3%. At baseline, the mean hemoglobin (Hb) was 97.4 +/- 13.2 g/L and ranged from 96.4 +/- 0.8 g/L to 98.3 +/- 0.8 g/L in various groups. At end of follow-up (day 270), a significant increase in Hb levels from baseline was observed in all treatment groups; however, the Hb gain (6.9 +/- 0.6 g/L) in group III and group V (3.64 +/- 0.56 g/L) differed significantly from the control group. A total of 155 students dropped out of the study due to various reasons not related to treatment. No adverse side-effect of Ayurvedic medication was noted in any student.
We conclude that a daily dose of Sootshekhar Rasa (250 mg) plus Sitopaladi Churna (400 mg) can produce sustainable improvement of nutritional anemia in adolescent students.
贫血是印度学龄儿童的一个严重健康问题。非妊娠青春期少女贫血的患病率很高。进行了一项调查，以研究两种不含铁的阿育吠陀制剂——苏特舍卡尔拉莎（Sootshekhar Rasa）加西托帕拉迪丘尔纳（Sitopaladi Churna）——对改善青少年学生营养性贫血的影响。
这是一项单盲、随机、对照研究。
印度北部德拉敦地区。
受试者共有 1646 名年龄在 11-18 岁之间的男女生，他们在德拉敦地区的学校上学。
根据世界卫生组织的指南，共有 1322 名青春期贫血学生被随机分为 5 组。第 I 组（对照组）学生接受淀粉治疗。第 II、III 和 IV 组学生分别接受苏特舍卡尔拉莎（Sootshekhar Rasa）加西托帕拉迪丘尔纳（Sitopaladi Churna）的不同组合，即每天 125 毫克苏特舍卡尔拉莎（Sootshekhar Rasa）加 500 毫克西托帕拉迪丘尔纳（Sitopaladi Churna）、每天 250 毫克苏特舍卡尔拉莎（Sootshekhar Rasa）加 400 毫克西托帕拉迪丘尔纳（Sitopaladi Churna）和每周 250 毫克苏特舍卡尔拉莎（Sootshekhar Rasa）加 400 毫克西托帕拉迪丘尔纳（Sitopaladi Churna）。第 V 组学生接受铁和叶酸片治疗。所有学生接受治疗 90 天，并在接下来的 180 天进行随访。
结果测量是评估苏特舍卡尔拉莎（Sootshekhar Rasa）加西托帕拉迪丘尔纳（Sitopaladi Churna）在改善营养性贫血方面的效果。
贫血的总患病率为 81.3%。基线时，平均血红蛋白（Hb）为 97.4+/-13.2g/L，各组范围为 96.4+/-0.8g/L 至 98.3+/-0.8g/L。在随访结束时（第 270 天），所有治疗组的 Hb 水平均较基线显著升高；然而，第 III 组和第 V 组（Hb 升高 6.9+/-0.6g/L）与对照组的 Hb 升高（3.64+/-0.56g/L）有显著差异。共有 155 名学生因各种与治疗无关的原因退出了研究。没有观察到任何学生对阿育吠陀药物有不良反应。
我们的结论是，每天服用苏特舍卡尔拉莎（250 毫克）加西托帕拉迪丘尔纳（400 毫克）可以持续改善青春期学生的营养性贫血。
